ArticleFrontiers in genetics2025
Development and validation of mPCR-CEFA for detecting multiple deletion and non-deletion thalassemia genotypes.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thalassemia is a common hereditary blood disorder caused by genetic variants in globin genes, leading to abnormal hemoglobin production. Rapid and accurate genotyping is essential for molecular screening and prenatal genetic diagnosis to prevent the birth of individuals with severe forms of the disease. Methods: We developed a multiplex PCR-capillary electrophoresis fragment analysis (mPCR-CEFA) method to detect 16 α-thalassemia and 24 β-thalassemia genotypes simultaneously. Genomic DNA extracted from clinical blood samples underwent a two-tube multiplex PCR amplification. The amplification products were analyzed using capillary electrophoresis to detect mutation peaks in different fluorescent channels and to calculate α1/α2 and Y1/Y2 ratios for genotype determination. The performance of mPCR-CEFA was validated against conventional methods, including Gap-PCR and PCR-RDB. Results: The α1/α2 and Y1/Y2 peak ratios exhibited stable and reproducible values, allowing for precise genotyping of thalassemia events involving homologous recombination, such as -α Conclusion: The mPCR-CEFA method is a reliable, efficient, and scalable tool for genetic diagnosis of thalassemia. Its ability to detect multiple genotypes simultaneously and resolve complex cases makes it particularly valuable for large-scale screening and clinical applications. This approach holds significant potential for improving thalassemia prevention strategies and supporting public health efforts in high-prevalence regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.